saxenda glp-1 diabetes market impact Agonists Weight Loss Drugs Report, 2025-2030 Liraglutide (Saxenda) - Obesity treatment

With an estimated $130 billion market by 2030, I believe that the market is overreacting to the current short-term issues

SilverSneakers and Tivity Health are not affiliated with, and do not endorse, any medication or manufacturer Frontiers | GLP-1 agonists and exercise: the future of lifestyle prioritization Participating locations (PL) are not owned or operated by Tivity Health, Inc

Thats only if your insurance covers it which requires a fairly extensive PA process

Mixed experiences in customer support but fulfillment delays reported

It can also speed up the browning of white adipose tissue, so theres more BAT to be burned for body heat

Medications can replace or stabilize what the body cannot produce, allowing for better symptom management and overall long-term well-being